Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.

Oncotarget - 28 Aug 2015

Sharma Ramaswamy, Williams Paul J, Gupta Anjana, McCluskey Brandon, Bhaskaran Shylesh, Muñoz Steve, Oyajobi Babatunde O

Abstract excerpt

Treatment of multiple myeloma with bortezomib can result in severe adverse effects, necessitating the development of targeted inhibitors of the proteasome. We show that stable expression of a dominant-negative F-box deleted (âF) mutant of the E3 ubiquitin ligase, SCFβ-TrCP/FWD1, in murine 5TGM1 myeloma cells dramatically attenuated their skeletal engraftment and survival when inoculated into immunocompetent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caspase 3

Share to Multiple Myeloma

Share to Neoplasm Transplantation

Share to Proteasome Endopeptidase Complex

Share to Pyrrolidines

Share to Stromal Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 26009993
DOI: 10.18632/oncotarget.4120
PMCID: PMC4673288

Genes

TNF
ATF4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice.PMID 26009993Read ↗

Immune-mediated tumor control in the 5TGM1 transfer model of multiple myelomaSemantic proximity Read ↗

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myelomaSemantic proximity Read ↗

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myelomaSemantic proximity Read ↗

LAGλ-1: A clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myelomaSemantic proximity Read ↗

Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myelomaSemantic proximity Read ↗

Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.Semantic proximity Read ↗

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse modelSemantic proximity Read ↗

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myelomaSemantic proximity Read ↗

Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of MyelomaSemantic proximity Read ↗

Marked Osteoblastopenia and Reduced Bone Formation in a Model of Multiple Myeloma Bone Disease in Severe Combined Immunodeficiency MiceSemantic proximity Read ↗

Blimp1 is limiting for transformation in a mouse plasmacytoma model.Semantic proximity Read ↗

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.